Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity ...

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, potentially securing long-term revenue streams for the biopharmaceutical ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $470, Citizens JMP analysts reiterated their ...

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

REZDIFFRA INTERACTION WITH CANNABIS OR CBD. Cannabis (often called marijuana) and cannabis products, such as cannabidiol (CBD), have not been specifically reported to interact with Rezdiffra.

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain my Hold rating on MDGL stock.

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant ...

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in ...